Our Publications
From the lab
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
The Journal of Clinical Investigation, 2018, 128(10):4654-4688
Hsu J.+, Hodgins J.J.+, Marathe M., Nicolai C.J., Bourgeois-Daigneault M.C., Trevino T.N., Azimi C.S., Scheer A.K., Randolph H.E., Thompson T.W., Zhang L., Iannello A., Mathur N., Jardine K.E., Kirn G.A., Bell J.C., McBurney M.W., Raulet D.H.*, Ardolino M.*
*co-corresponding authors and co-senior authors
Killers 2.0: NK Cell Therapies at the Forefront of Cancer Control.
The Journal of Clinical Investigation, 2019, 129(9):3499-3510
Hodgins J.J., Khan S.T., Park M., Auer R.C., Ardolino M.
Is Innate Immunity our best weapon for flattening the curve?
The Journal of Clinical Investigation, 2020, 130(8):3954-3956
Angka L., Market M., Ardolino M.*, Auer R.C.*
*corresponding author and co-senior author
Flattening the COVID-19 curve with Natural Killer cell based immunotherapies
Frontiers in Immunology, 2020, 11:1512
Market M., Angka L., Martel A., Bastin D., Olanubi O., Tennakoon G., Boucher D., Ng J., Ardolino M.*, Auer R.C.*
*corresponding author and co-senior author
The two faces of NK cells in oncolytic virotherapy
Cytokines and Growth Factors Reviews, 2020, 11:1512
Marotel M., Hasim M.S., Hagerman A., Ardolino M.
Immunotherapy for sarcomas: new frontiers and unveiled opportunities.
Journal of Immunotherapy of Cancer, 2021, 9(2):e001580
K. Birdi#, A. Jirovec#, S. Cortés-Kaplan#, J. Werier, C. Nessim, J.S. Diallo*, M. Ardolino*
#: equal contribution / *: equal contribution
When Killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer
Science Advances, 2022, 8(15)
Hasim M.S.†, Marotel M.†, Hodgins J.J., Vulpis E., Makinson O.J., Asif S., Shih H.Y., Scheer A.K., MacMillan O., Alonso F.G., Burke K.P., Cook D.P., Li R., Petrucci M.T., Santoni A., Fallon P.G., Sharpe A.H., Sciumè G., Veillette A., Zingoni A., Gray D.A., McCurdy A., Ardolino M.
†: equal contribution
A new functional screening platform identifies colistin sulfate as an enhancer of Natural Killer cell cytotoxicity.
Cancers, 2022, 14(12), 2832
Cortés-Kaplan S., Hasim M.S., Kaczmarek S., Taha Z., Maznyi G., McComb S., Lee S.H., Diallo J.S., Ardolino M.
More than a ligand: PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I interferon pathway
Submitted to BioRxiv
Hodgins J.J., Abou-Hamad J., Hagerman A., Yakubovich E., Tanese de Souza C., Marotel M., Buchler A., Fadel S., Park M., Fong-McMaster C., Crupi M., Bell J.C., Harper M-E., Rotstein B.H., Auer R.C., Vanderhyden B., Sabourin L., Bourgeois-Daigneault M.C., Cook D., Ardolino M.
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.
Front. In Immunol., 2023, 14
Kilgour M.K., Bastin D.J., Lee S.H.*, Ardolino M.*, McComb S.*, Visram A.*
*co-senior author
Collaborations
Loss of Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers.
Oncogene, 2020, 39(23):4592-4602
Al-Zahrani K., Abou-Hamad J., Pryce B., Cook D., Hodgins J.J., Labreche C., Robineau‑Charette P., de Souza C., Bell J.C., Auer R.C., Ardolino M., Vanderhyden B., Sabourin L.
Muscle-Specific Deletion of SLK/Stk2 Enhances p38 Activity and Myogenesis in mdx Mice
BBA Molecular Cell Research, 2021, 1868(2), 118917
Pryce B.P., Labreche C., Hamoudi D., Abou-Hamad J., Al-Zahrani K.N., Hodgins J.J., Boulanger-Piette A., Bossé S., Balog-Alvarez C., Frenette J., Ardolino M., Kornegay J.N., Sabourin L.
Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver
European Journal of Immunology, 2021, 51(11):2568-2575
Di Censo C., Marotel , Mattiola I., Müller L., Scarno G., Pietropaolo G., Peruzzi G., Laffranchi M., Mazej J., Hasim M.S., Asif S., Russo E., Tomaipitinca L., Stabile H., Lee S.H., Vian L., Gadina M., Gismondi A., Shih H.-Y., Mikami Y., Bernardini G., Bonelli M., Sozzani S., Diefenbach A., Ardolino M., Santoni A., Sciumè G.
iScience, 2022, 25(12):105524
Abou-Hamad J, Hodgins JJ, de Souza CT, Garland B, Labrèche C, Marotel M, Gibson C, Delisle S, Pascoal J, Auer RC, Ardolino M, Sabourin L
Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.
Nature Communications, 2023, 14
Azad T., Rezaei R., Singaravelu R., Pelin A., Boulton S., Petryk J., Onsu K.A., Martin N.T., Hoskin V., Ghahremani M., Marotel M., Marius R., He X., Crupi M.J.F., Hoang H-D., Nik-Akhtar A., Ahmadi M., Zamani N.K., Golshani A., Alain T., Greer P., Ardolino M., Dickinson B.C., Tai L-H., Ilkow C.S., Bell J.C.
Contact Us
Address: Ottawa Hospital Research Institute – 501 Smyth Road – Cancer Center – Ottawa, ON K1H 8M2
Tel: 613-737-8899 ext 77253
Mail: mardolino@ohri.ca
Legal Informations
Made with love by Qweeble